Study Evaluating ERB-041 in Active Crohn's Disease

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohn's disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Men and women, minimum 18 years of age with a diagnosis of Crohn's disease greater than 3 months,

• Eligible subjects must have adequate hematologic, renal, and hepatic function.

Other inclusions apply

Exclusion Criteria:

• Use of the following medications within the specified time period before randomization is prohibited:

Within 48 hours before randomization

• Nonsteroidal antiinflammatory drugs (NSAIDs) Within 2 weeks before randomization

• Herbal supplements (except for a daily multivitamin/mineral supplement not containing herbal components).

Other exclusions applies